Top Page
VentriPoint Diagnostics
(VPT)
VentriPoint Diagnostics (VPT) vs. iShares MSCI Canada ETF (EWC)
VentriPoint Diagnostics Business Overview & Revenue Model
VentriPoint Diagnostics Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 175.62K | 95.17K | 49.18K | 68.17K | 0.00 | 36.02K |
| Gross Profit | 144.92K | 95.17K | 42.43K | 57.81K | -48.81K | 26.27K |
| EBITDA | -3.66M | -4.76M | -4.74M | -4.79M | -3.81M | -1.58M |
| Net Income | -4.06M | -4.92M | -4.87M | -4.87M | -3.88M | -1.85M |
Balance Sheet | ||||||
| Total Assets | 377.12K | 658.02K | 1.88M | 5.98M | 9.54M | 801.57K |
| Cash, Cash Equivalents and Short-Term Investments | 68.32K | 60.55K | 1.29M | 5.19M | 9.27M | 526.03K |
| Total Debt | 2.35M | 1.63M | 412.44K | 459.08K | 159.97K | 1.37M |
| Total Liabilities | 5.03M | 3.64M | 1.69M | 1.42M | 1.21M | 3.15M |
| Stockholders Equity | -4.66M | -2.98M | 189.71K | 4.55M | 8.33M | -2.35M |
Cash Flow | ||||||
| Free Cash Flow | -1.68M | -3.39M | -3.80M | -4.14M | -3.15M | -1.10M |
| Operating Cash Flow | -1.68M | -3.39M | -3.80M | -4.14M | -3.15M | -1.10M |
| Investing Cash Flow | 0.00 | 0.00 | 0.00 | 0.00 | -4.26K | -3.76K |
| Financing Cash Flow | 1.65M | 2.20M | -102.36K | 87.65K | 11.89M | 1.62M |
VentriPoint Diagnostics Technical Analysis
VentriPoint Diagnostics Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
55 Neutral | C$427.52M | -6.31 | -127.60% | ― | 72.03% | -1.47% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | C$20.96M | -5.04 | ― | ― | 28.59% | 23.46% | |
46 Neutral | C$31.91M | -1.43 | -181.70% | ― | 209.29% | 35.38% | |
46 Neutral | C$50.13M | -11.14 | -269.41% | ― | 1.46% | 6.91% | |
46 Neutral | C$11.37M | -7.97 | ― | ― | ― | 9.21% |
VentriPoint Diagnostics Corporate Events
Ventripoint Diagnostics Ltd. has doubled the size of its previously announced non-brokered private placement from $500,000 to $1,000,000 after strong investor demand, subject to TSX Venture Exchange approval. The financing consists of units made up of one common share and one warrant, with warrants exercisable at $0.13 for 24 months and subject to potential accelerated expiry, and may include finder’s fees and finder warrants of up to 8% of gross proceeds. Proceeds are earmarked for key commercialization initiatives, manufacturing scale-up, continued regulatory submissions and general operational needs, underscoring an aggressive push to expand market adoption of its AI-based cardiac imaging technology while reinforcing its capital position in a competitive medtech landscape.
The most recent analyst rating on (TSE:VPT) stock is a Hold with a C$0.12 price target. To see the full list of analyst forecasts on VentriPoint Diagnostics stock, see the TSE:VPT Stock Forecast page.
Ventripoint Diagnostics Ltd. has launched a non-brokered private placement of up to 5,000,000 units at $0.10 per unit to raise as much as $500,000, subject to TSX Venture Exchange approval. Each unit consists of one common share and one warrant exercisable at $0.13 for 24 months, with the company reserving the right to accelerate warrant expiry if its shares trade at higher levels, and may include finder’s fees and associated warrants; proceeds are earmarked for sales and marketing, hiring additional key personnel, and general working capital, underscoring Ventripoint’s efforts to strengthen operations and support the commercial rollout of its AI-driven cardiac imaging solutions.
The most recent analyst rating on (TSE:VPT) stock is a Hold with a C$0.12 price target. To see the full list of analyst forecasts on VentriPoint Diagnostics stock, see the TSE:VPT Stock Forecast page.
Ventripoint Diagnostics has engaged consulting firm Summit Sciences and its CEO Dana Friesen to develop advanced, customer-focused financial and return-on-investment models that quantify the economic benefits of adopting the company’s AI-driven VMS+ cardiac imaging system. By incorporating real-world data and advanced analytics, the partnership aims to demonstrate cost savings, operational efficiencies and improved clinical outcomes for hospitals and cardiology providers, supporting Ventripoint’s broader strategy to accelerate commercialization and global uptake of its MRI-alternative ultrasound technology while addressing health system sustainability and access in diverse care settings.
Ventripoint Diagnostics Ltd. announced its plan to issue 1,145,627 common shares to satisfy $103,106.29 in debenture interest payments, subject to TSXV approval. This initiative demonstrates the company’s strategic approach to manage its financial commitments without affecting ownership control, showcasing stability and operational strategy in the healthcare diagnostics industry.
Ventripoint Diagnostics has announced a partnership with the Nisg̱a’a Valley Health Authority to develop a global model for delivering advanced cardiac imaging to remote and Indigenous communities. This new hub-and-spoke model aims to provide high-quality heart care without the need for long-distance travel or high costs, using Ventripoint’s VMS+™ system to enhance standard echocardiograms. The initiative will start with the Nisg̱a’a Valley Health Authority as the first remote site and plans to expand to additional First Nations communities, Arctic regions, and rural areas worldwide. This collaboration is expected to improve access to cardiac diagnostics and advance health sovereignty for the Nisg̱a’a people, with potential implications for universal access to affordable cardiac care globally.
Ventripoint Diagnostics has appointed David Swetlow as Chief Financial Officer, marking a significant step in strengthening its leadership team as the company enters a new growth phase. Swetlow’s extensive experience in financial and public company leadership across high-growth medical technology and life sciences sectors is expected to be instrumental in advancing Ventripoint’s commercial strategy, particularly in the global rollout of its AI-powered VMS+™ cardiac imaging platform. This strategic appointment aims to enhance Ventripoint’s market positioning and support its expansion into new markets, driving revenue growth and strengthening global partnerships.
Ventripoint Diagnostics Ltd. has announced a debt settlement agreement, converting $542,591.50 of debt into 5,425,915 common shares at $0.10 per share, subject to a hold period and TSX Venture Exchange approval. This move aims to conserve cash for business development, potentially strengthening Ventripoint’s financial position and operational capabilities.
Ventripoint Diagnostics has announced a collaboration with Providence Health Care Ventures to validate its AI-enabled VMS+™ platform at St. Paul’s Hospital in Vancouver. This partnership aims to demonstrate how the platform can reduce the reliance on cardiac MRIs by providing accurate cardiac measurements earlier in the diagnostic process, potentially improving access to advanced heart diagnostics, especially in underserved communities. The collaboration will assess the platform’s integration into clinical workflows, its impact on reducing MRI referrals and wait times, and the associated cost efficiencies, with the goal of extending advanced cardiac diagnostics to rural and Indigenous communities.
Ventripoint Diagnostics Ltd. has announced advancements in its business plan, focusing on the commercialization of its VMS+™ system by transitioning its user base from research to routine clinical adoption. The company is expanding its commercial team and evolving its marketing strategies to better align with market needs, aiming to improve patient outcomes and streamline the sales process. Ventripoint is also enhancing customer training and support, particularly in clinical integration, to facilitate the adoption of VMS+™ in routine care pathways. These efforts are expected to reduce the need for secondary imaging and improve diagnostic confidence, positioning Ventripoint to capitalize on the growing heart valve repair and replacement market.